<SEC-DOCUMENT>0001206774-17-003057.txt : 20171101
<SEC-HEADER>0001206774-17-003057.hdr.sgml : 20171101
<ACCEPTANCE-DATETIME>20171101094718
ACCESSION NUMBER:		0001206774-17-003057
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171101
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171101
DATE AS OF CHANGE:		20171101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-20859
		FILM NUMBER:		171167579

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>geron3313903-8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">

<P align=center><B><FONT face="Times New Roman" size=2>UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman" size=2>SECURITIES AND
EXCHANGE COMMISSION<BR>WASHINGTON, D.C. 20549 <BR>___________<BR></FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>FORM 8-K </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>CURRENT
REPORT<BR></FONT></B><B><FONT face="Times New Roman" size=2>PURSUANT TO SECTION
13 OR 15(d) OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></B></P>
<P align=center><FONT face="Times New Roman" size=2>Date of Report (Date of
Earliest Event Reported): </FONT><B><FONT face="Times New Roman" size=2>November
1, 2017</FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=2>GERON
CORPORATION<BR></FONT></B><FONT face="Times New Roman" size=2>(Exact name of
registrant as specified in its charter) </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>Delaware</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>0-20859</FONT></B></TD>
    <TD noWrap style="text-align: center" width="33%"><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(State or
      other jurisdiction of</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(Commission
      File Number)</FONT></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>(IRS
      Employer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>incorporation)</FONT></TD>
    <TD noWrap align=left width="33%"></TD>
    <TD noWrap style="text-align: center" width="33%"><FONT face="Times New Roman" size=2>Identification No.)</FONT></TD></TR></TABLE>
<P align=center><B><FONT face="Times New Roman" size=2>149 COMMONWEALTH DRIVE,
SUITE 2070<BR>MENLO PARK, CALIFORNIA 94025<BR></FONT></B><FONT face="Times New Roman" size=2>(Address of principal executive offices, including
zip code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>(650)
473-7700<BR></FONT></B><FONT face="Times New Roman" size=2>(Registrant's
telephone number, including area code) </FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>N/A<BR></FONT></B><FONT face="Times New Roman" size=2>(Former name or former address, if changed since
last report) </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=1 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-right: 8pt; vertical-align: top"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD STYLE="text-align: left; width: 99%; vertical-align: top"><FONT face="Times New Roman" size=2>Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-right: 8pt; vertical-align: top"></TD>
    <TD STYLE="text-align: left; width: 99%; vertical-align: top"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-right: 8pt; vertical-align: top"><FONT face="Times New Roman" size=2>&#9744;</FONT></TD>
    <TD STYLE="text-align: left; width: 99%; vertical-align: top"><FONT face="Times New Roman" size=2>Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</FONT></TD></TR>
  <TR>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-right: 8pt; vertical-align: top"></TD>
    <TD STYLE="text-align: left; width: 99%; vertical-align: top"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-right: 8pt; vertical-align: top"><FONT size=2 face="Times New Roman">&#9744;<FONT face="Times New Roman"></FONT></FONT></TD>
    <TD STYLE="text-align: left; width: 99%; vertical-align: top"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-right: 8pt; vertical-align: top"></TD>
    <TD STYLE="text-align: left; width: 99%; vertical-align: top"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD NOWRAP STYLE="text-align: left; width: 1%; padding-right: 8pt; vertical-align: top"><FONT size=2 face="Times New Roman">&#9744;<FONT face="Times New Roman"></FONT></FONT></TD>
    <TD STYLE="text-align: left; width: 99%; vertical-align: top"><FONT face="Times New Roman" size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman" size=2>Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Emerging growth company
&#9744;</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>
<P align=left><B><FONT face="Times New Roman" size=2>Item 8.01 Other Events.
</FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>On November 1, 2017, Geron
Corporation issued a press release entitled &#147;Geron Announces Presentations at American
Society of Hematology Annual Meeting&#148; which describes the abstracts related to
the telomerase inhibitor imetelstat that have been accepted for presentation at
the 59th American Society of Hematology (ASH) Annual Meeting and Exposition to
be held in Atlanta, Georgia from December 9-12, 2017. A copy of the press
release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference. In addition, a copy of the abstract entitled
&#147;Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent (TD) IPSS
Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA)
(IMerge)&#148; is attached as Exhibit 99.2 to this Current Report on Form 8-K and is
incorporated herein by reference. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Item 9.01. Financial
Statements and Exhibits. </FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 30pt"><FONT face="Times New Roman" size=2>(d) Exhibits.</FONT></P>
<TABLE style="LINE-HEIGHT: normal; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="1%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="1%"><B><FONT face="Times New Roman" size=2>Exhibit Number</FONT></B></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="100%"><B><FONT face="Times New Roman" size=2>Description</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="1%"></TD>
    <TD noWrap style="text-align: center" width="1%" bgColor=#c0c0c0><A HREF="geron3313903-ex991.htm" STYLE="-sec-extract: exhibit"><FONT face="Times New Roman" size=2>99.1</FONT></A></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="100%" bgColor=#c0c0c0><A HREF="geron3313903-ex991.htm" STYLE="-sec-extract: exhibit"><FONT face="Times New Roman" size=2>Press
      Release dated November 1, 2017.</FONT></A></TD></TR>
  <TR vAlign=bottom>
    <TD vAlign=top noWrap align=center width="1%"></TD>
    <TD vAlign=top noWrap align=center width="1%"><A HREF="geron3313903-ex992.htm" STYLE="-sec-extract: exhibit"><FONT face="Times New Roman" size=2>99.2</FONT></A></TD>
    <TD vAlign=top align=left width="1%"></TD>
    <TD vAlign=top align=left width="100%"><A HREF="geron3313903-ex992.htm" STYLE="-sec-extract: exhibit"><FONT face="Times New Roman" size=2>ASH Abstract
      entitled, &#147;Efficacy and Safety of Imetelstat in RBC Transfusion-Dependent
      (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to Erythropoiesis-Stimulating
      Agents (ESA) (IMerge)&#148;</FONT></A></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>1 </FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>
<P align=center><B><FONT face="Times New Roman" size=2>SIGNATURE </FONT></B></P>
<P ALIGN="LEFT" STYLE="text-indent: 15pt"><FONT face="Times New Roman" size=2>Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD align=left width="50%" colSpan=2><FONT face="Times New Roman" size=2>GERON
      CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="100%" colSpan=3>&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"><FONT face="Times New Roman" size=2>Date:
      November 1, 2017</FONT></TD>
    <TD noWrap align=left width="1%"><FONT size=2 face="Times New Roman">By:</FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="49%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;/s/ Stephen N. Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;Stephen N.
      Rosenfield</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;Executive
      Vice President, General</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="50%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>&nbsp;&nbsp;Counsel and
      Corporate Secretary</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman" size=2>2 </FONT></P>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>geron3313903-ex991.htm
<DESCRIPTION>PRESS RELEASE DATED NOVEMBER 1, 2017
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">

<P align=center><B><FONT face="Times New Roman" size=2>Geron Announces
Presentations at American Society of Hematology Annual Meeting </FONT></B></P>
<P align=center><I><FONT face="Times New Roman" size=2>Imetelstat Clinical Data
from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented
</FONT></I></P>
<P align=left><B><FONT face="Times New Roman" size=2>MENLO PARK, Calif.,
November 1, 2017 </FONT></B><FONT face="Times New Roman" size=2>-- Geron
Corporation (Nasdaq: GERN) today announced that four abstracts related to the
telomerase inhibitor imetelstat have been accepted for presentation at the 59th
American Society of Hematology (ASH) Annual Meeting and Exposition to be held in
Atlanta, Georgia from December 9-12, 2017. The abstracts were published today on
the ASH website at www.hematology.org. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Clinical Data Presentation
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>An abstract containing data
from the first 32 patients enrolled in Part 1 of IMerge, the ongoing Phase 2/3
clinical trial of imetelstat in patients with lower risk myelodysplastic
syndromes (MDS) being conducted by Janssen Research &amp; Development, LLC., was
accepted for a poster presentation. </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Title: </FONT><B><I><FONT face="Times New Roman" size=2>Efficacy and Safety of Imetelstat in RBC
Transfusion-Dependent (TD) IPSS Low/Int-1 MDS Relapsed/Refractory to
Erythropoiesis-Stimulating Agents (ESA) (IMerge) </FONT></I></B><FONT face="Times New Roman" size=2>(Abstract #4256)<BR>Date: Monday, December 11,
2017<BR>Time: 6:00 p.m. &#150; 8:00 p.m. ET </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Pre-Clinical Data
Presentations </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Three abstracts by academic
collaborators were selected for presentation that build on previous studies
investigating imetelstat&#146;s effects and mechanism of action in pre-clinical
models of hematologic myeloid malignancies.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Title: </FONT><B><I><FONT face="Times New Roman" size=2>Imetelstat, a Telomerase Inhibitor, Is Capable of
Depleting Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells
</FONT></I></B><FONT face="Times New Roman" size=2>(Abstract #1654)<BR>Date:
Saturday, December 9, 2017<BR>Time: 5:30 p.m. - 7:30 p.m. ET </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Title: </FONT><B><I><FONT face="Times New Roman" size=2>Telomerase Inhibition Impairs Self-Renewal of
b-Catenin Activated Myeloproliferative Neoplasm Progenitors </FONT></I></B><FONT face="Times New Roman" size=2>(Abstract #2860)<BR>Date: Sunday, December 10,
2017<BR>Time: 6:00 p.m. &#150; 8:00 p.m. ET </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Title: </FONT><B><I><FONT face="Times New Roman" size=2>Integrated Molecular Analysis Identifies
Replicative Stress as Sensitizer to Imetelstat Therapy in AML
</FONT></I></B><FONT face="Times New Roman" size=2>(Abstract
#798)<BR></FONT><FONT face="Times New Roman" size=2>Date: Monday, December 11,
2017<BR>Time: 5:45 p.m. ET </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>In accordance with ASH
policies, abstracts submitted to the ASH Annual Meeting are embargoed from the
time of submission. To be eligible for presentation at the ASH Annual Meeting,
any additional data or information to be presented at the Annual Meeting may not
be made public before the presentation. The imetelstat posters and slides will
be available in the &#147;R&amp;D&#148; section of Geron&#146;s website (www.geron.com)
following the ASH Annual Meeting presentations. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Webcast Investor
Event</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Following the clinical data
presentation at the ASH Annual Meeting, management will be hosting a live
webcast of an analyst and investor meeting on December 11, 2017 to discuss the
imetelstat clinical data in MDS presented. The audio
and slide presentation will be accessible at www.geron.com on the Investor
Relations pages, under Events. Following the live presentation, the webcast will
be archived and available for replay at the same address for a period of 30
days. </FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>
<P align=left><B><FONT face="Times New Roman" size=2>About Imetelstat
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Imetelstat (GRN163L;
JNJ-63935937) is a potent and specific inhibitor of telomerase that is
administered by intravenous infusion. This first-in-class compound, discovered
by Geron, is a specially designed and modified short oligonucleotide, which
targets and binds directly with high affinity to the active site of telomerase.
Preliminary clinical data suggest imetelstat might have disease-modifying
activity by inhibiting the progenitor cells of the malignant clones associated
with hematologic malignancies in a relatively select manner. Most commonly
reported adverse events in imetelstat clinical studies include fatigue,
gastrointestinal symptoms and cytopenias. Imetelstat has not been approved for
marketing by any regulatory authority. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>About the Collaboration
with Janssen </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>On November 13, 2014, Geron
entered into an exclusive worldwide license and collaboration agreement with
Janssen Biotech, Inc., to develop and commercialize imetelstat for oncology,
including hematologic myeloid malignancies, and all other human therapeutics
uses. Under the terms of the agreement, Geron received an upfront payment of $35
million and is eligible to receive additional payments up to a potential total
of $900 million for the achievement of development, regulatory and commercial
milestones, as well as royalties on worldwide net sales. All regulatory,
development, manufacturing and promotional activities related to imetelstat are
being managed through a joint governance structure, with Janssen responsible for
these activities. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>About Geron </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Geron is a clinical stage
biopharmaceutical company focused on the collaborative development of a
first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid
malignancies. For more information about Geron, visit www.geron.com. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Use of Forward-Looking
Statements</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Except for the historical  information contained herein, this press
release contains forward-looking  statements made pursuant to the &#147;safe harbor&#148; provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that  statements in this press release regarding: (i) the
ability of imetelstat to deplete myelofibrosis hematopoietic stem cells and progenitor cells; (ii) the safety and  efficacy
of imetelstat; (iii) potential receipt by Geron of additional payments  up to a potential total of $900 million for the
achievement of development,  regulatory and commercial milestones, and royalties from sales of imetelstat;  and (iv) other
statements that are not historical facts, constitute  forward-looking statements. These statements involve risks and
uncertainties  that can cause actual results to differ materially from those in such  forward-looking statements. These risks
and uncertainties, include, without  limitation, risks and uncertainties related to: (i) whether Janssen decides to continue
to conduct IMerge; (ii) whether imetelstat is safe and efficacious and  will succeed in IMerge by overcoming all of the
clinical safety and efficacy, technical, scientific, manufacturing and regulatory challenges; (iii) whether  the FDA or other
health authorities permit IMerge to continue to proceed under  the existing protocols or any amendments thereto; (iv) the
prospective ability of imetelstat to deplete myelofibrosis hematopoietic stem cells and progenitor cells may not result in
imetelstat being sufficiently efficacious to be approved for commercial use in any disease indication; (v) Geron&#146;s
dependence on Janssen for the development, regulatory approval, manufacture and commercialization of imetelstat, including
the risks that if Janssen were to breach or terminate the collaboration agreement or  otherwise fail to successfully develop
and commercialize imetelstat and in a  timely manner, or at all, Geron would not obtain the anticipated financial and other
benefits of the collaboration agreement with Janssen and the clinical development or commercialization of imetelstat could be
delayed or terminated;  (vi) whether any future efficacy or safety results from any clinical trial of imetelstat may cause
the benefit/risk profile of imetelstat to become unacceptable; and (vii) whether patent coverage of imetelstat enables
Janssen to successfully commercialize imetelstat. Additional information on the above-stated risks and uncertainties
and additional risks, uncertainties and factors that could cause actual results to differ materially from those in
the forward-looking statements are </FONT><FONT face="Times New Roman" size=2>contained in Geron&#146;s periodic reports
filed with the Securities and Exchange Commission under the heading &#147;Risk Factors,&#148; including Geron&#146;s
quarterly report on Form 10-Q for the quarter ended June 30, 2017. Undue reliance should not be placed on forward-looking
statements, which speak only as  of the date they are made, and the facts and assumptions underlying the forward-looking
statements may change. Except as required by law, Geron  disclaims any obligation to update these forward-looking statements
to reflect future information, events or circumstances. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>CONTACT: </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Anna Krassowska,
Ph.D.<BR>Investor and Media
Relations<BR>650-473-7765<BR>investor@geron.com<BR>media@geron.com </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>### </FONT></P>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>geron3313903-ex992.htm
<DESCRIPTION>ASH ABSTRACT
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor="#ffffff">

<P align=center><B><FONT face="Times New Roman" size=2>Efficacy and Safety of
Imetelstat in RBC Transfusion-Dependent (TD) IPSS Low/Int-1
MDS<BR>Relapsed/Refractory to Erythropoiesis-Stimulating Agents (ESA)
(IMerge)</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2><U>Pierre Fenaux<SUP>1</SUP></U>,
Azra Raza, MD<SUP>2</SUP>, Edo Vellenga, MD<SUP>3</SUP>, Uwe
Platzbecker<SUP>4</SUP>, Valeria Santini, MD<SUP>5</SUP>, Irina
Samarina<SUP>6*</SUP>, Koen Van Eygen, MD<SUP>7*</SUP>, Maria
D&#237;ez-Campelo<SUP>8*</SUP>, Mrinal M Patnaik, MD, MBBS<SUP>9</SUP>, Laurie
Sherman, BSN<SUP>10</SUP>, Libo Sun<SUP>11*</SUP>, Helen Varsos, MS,
RPh<SUP>11*</SUP>, Esther Rose<SUP>11*</SUP>, Aleksandra Rizo, MD, PhD<SUP>11
</SUP></FONT><FONT face="Times New Roman" size=2>and David P. Steensma,
MD<SUP>12</SUP></FONT></P>
<P align=left><FONT face="Times New Roman" size=2><SUP>1</SUP>H&#244;pital St Louis,
Paris, France; </FONT><FONT face="Times New Roman" size=2><SUP>2</SUP>Columbia
Presbyterian, New York, NY; </FONT><FONT face="Times New Roman" size=2><SUP>3</SUP>UMCG, Groningen, Netherlands; </FONT><FONT face="Times New Roman" size=2><SUP>4</SUP>Universit&#228;tsklinikum Carl Gustav Carus
Dresden, Dresden, Germany; </FONT><FONT face="Times New Roman" size=2><SUP>5</SUP>AOU Careggi-University of Florence, Firenze, Italy;
</FONT><FONT face="Times New Roman" size=2><SUP>6</SUP>Emergency Hospital of
Dzerzhinsk, Nizhny Novgorod, Russian Federation; </FONT><FONT face="Times New Roman" size=2><SUP>7</SUP>AZ Groeninge &#150; Oncology Centre, Kortrijk,
Belgium; </FONT><FONT face="Times New Roman" size=2><SUP>8</SUP>Hosp. Clinico
Univ. De Salamanca, De Salamanca, Spain; </FONT><FONT face="Times New Roman" size=2><SUP>9</SUP>Mayo Clinic Rochester, Rochester, MN; <SUP>10</SUP>Janssen Research
&amp; Development, LLC, Spring House, PA; </FONT><FONT face="Times New Roman" size=2><SUP>11</SUP>Janssen Research &amp; Development, LLC,
Raritan, NJ; </FONT><FONT face="Times New Roman" size=2><SUP>12</SUP>Dana-Farber
Cancer Institute, Boston, MA </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Background:
</FONT></B><FONT face="Times New Roman" size=2>There are limited treatment
options for anemic patients with lower-risk MDS who are relapsed after or are
refractory to ESA. Imetelstat is a novel, first-in-class telomerase inhibitor
that targets cells with short telomere lengths and highly active telomerase, and
has clinical activity in myeloid malignancies (</FONT><I><FONT face="Times New Roman" size=2>Cancer Res </FONT></I><FONT face="Times New Roman" size=2>2014;4:362; </FONT><I><FONT face="Times New Roman" size=2>NEJM
</FONT></I><FONT face="Times New Roman" size=2>2015;373:920; </FONT><I><FONT face="Times New Roman" size=2>NEJM </FONT></I><FONT face="Times New Roman" size=2>2015;373:908; </FONT><I><FONT face="Times New Roman" size=2>BJC
</FONT></I><FONT face="Times New Roman" size=2>2016;6:e405). Targeting MDS
clones with imetelstat may improve outcomes including anemia in MDS patients
relapsed/refractory to ESA. We explored the safety and efficacy of imetelstat in
RBC TD patients with IPSS Low or Intermediate-1 (Int-1) risk MDS
relapsed/refractory to ESA. </FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Methods: </FONT></B><FONT face="Times New Roman" size=2>IMerge is
an ongoing 2-part, global, multicenter  study in TD patients (planned enrollment 200) with Low or Int-1 IPSS risk
MDS relapsed/refractory to ESAs and with </FONT><FONT face="Times New Roman" size=2>transfusion requirement of &#8805;4
units over 8 weeks prior to study entry. ESA-na&#239;ve patients with </FONT><FONT face="Times New Roman" size=2>sEPO &gt;500
mU/mL are also eligible. Part 1 is an  open- label, single-arm study assessing the efficacy and safety of imetelstat
administered IV every 4 weeks at a dose of 7.5 mg/kg. Part 2 is a double-blind,  randomized design comparing the efficacy of
imetelstat to placebo. The primary  </FONT><FONT face="Times New Roman" size=2>endpoint is the rate of RBC
transfusion-independence (TI) lasting &#8805;8 weeks. Key secondary endpoints include safety, rate of &#8805;24-week TI,
time to and duration of TI, and hematologic </FONT><FONT face="Times New Roman" size=2>improvement (HI) rate. Here we
report findings  from the 32 patients enrolled in Part 1 with a median follow up of 48 weeks.  </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>1 </FONT></P>
<HR align=center width="100%" noShade size="2">

<DIV style="PAGE-BREAK-BEFORE: always"></DIV>
<P align=left><B><FONT face="Times New Roman" size=2>Results: </FONT></B><FONT face="Times New Roman" size=2>29
(91%) patients had ECOG 0&#150;1, median age was  68.5 years. 59% of patients were IPSS Low and 41% Int-1. 13 patients (43%)
had sEPO&gt;500 mU/mL. 34% had a cytogenetic abnormality, including 22% with  del(5q). Prior treatments for MDS included
ESAs (88%), lenalidomide (38%), and  decitabine or azacitidine (HMAs) (25%); 56% of patients were both lenalidomide  and
HMA na&#239;ve. Baseline median RBC transfusion burden was 6 units per 8 weeks  </FONT><FONT face="Times New Roman" size=2>(range:
4&#150;14). As of May 2017, RBC-TI &#8805;8-week was achieved in 34% of patients. Median time from treatment initiation to
onset of TI was 8 weeks with a median duration of TI of 19 weeks, while 16% of patients achieved &#8805;24-week TI. 63% of
patients achieved erythroid HI; transient platelet improvement was reported for one patient. Of the 13 lenalidomide and HMA
na&iuml;ve patients without del(5q), 54% achieved &#8805;8-week TI, 31% had &#8805; 24-week TI and 69% achieved erythroid HI.
TI response was 35% (6/17) and 38% (5/13) in patients with sEPO level &#8804;500 mU/L and &gt;500 mU/L, respectively. The
most frequently reported adverse events were cytopenias, including Grade &#8805;3 and 4 neutropenia in 66% and 41% of
patients, respectively and grade &#8805;3 and 4 thrombocytopenia in 50% and 19% of patients, respectively. Dose reductions or
cycle delays due to adverse events were required for 59% of patients. One patient experienced neutropenic fever and two
patients had grade 3 thrombocytopenia concurrent with grade 1 bleeding events both considered related to imetelstat; all
recovered without sequelae. 28 patients (88%) had reversible LFT elevations by at least one grade; 4 of these were by 2
grades. Reversible grade 3 elevations were reported in 3 patients.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Conclusions:
</FONT></B><FONT face="Times New Roman" size=2>In IPSS Low/Int-1 RBC transfusion
dependent MDS patients relapsed/refractory to ESA, TI was observed in 34% and
erythroid HI in 63% with imetelstat therapy. TI response appeared to be
independent of sEPO level. Reversible cytopenias were the most frequent adverse
events, which were generally manageable with dose reduction or delays. Elevated
LFTS were reversible. Patients who were na&#239;ve to lenalidomide and HMAs and who
lacked del(5q) had a higher rate of durable TI (54%) than other groups, which
should be further explored. </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>2 </FONT></P>
<HR align=center width="100%" noShade size="2">

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
